Yun Zhong Reiterates Buy on Ascendis, Citing Strong Product Momentum and Long-Term Growth with Unchanged $327 Price Target
Tip Ranks·- Wedbush analyst Yun Zhong reaffirmed a Buy rating on Ascendis Pharma with an unchanged price target of 327 dollars. - The rating is supported by strong quarterly execution, robust product momentum exceeding market expectations, and long-term growth prospects. - Management aims to reach 5 billion euros in sales by 2030 and over 10 billion euros in the next decade, backed by successful product launches.